tirzepatide and psoriatic arthritis Concomitant ixekizumab significantly improved disease activity and promoted weight reduction versus ixekizumab alone in adults with PsA and obesity or overweight in the TOGETHER-PsA phase 3b trial. Read The obesity–inflammation axis in psoriatic
Description
Our belief is that cost should not inhibit access to effective weight loss solutions
(2) Medication list & recent medication changes
Its multi-receptor activity offers a novel strategy in metabolic disease, combining appetite suppression, insulin modulation, and increased energy expenditure
Gastroenterology, S0016-5085(16)00183-9
Primary care physicians should be aware that this drug might cause DR progression, so were suggesting that before they start a patient on semaglutide, they should discuss it with an ophthalmologist. Need for caution
HP and JD performed statistical analysis
